VISTA/B7-H5 Protein, Cynomolgus (HEK293, His)

VISTA/B7-H5 Protein is a B7 family member that maintains T cell and myeloid quiescence and is a promising target for combination cancer immunotherapy. VISTA not only acts as a ligand expressed on antigenpresenting cells, but also functions as a receptor on T cells. VISTA inhibits T cell activation, proliferation, and cytokine production. VISTA/B7-H5 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived VISTA/B7-H5 protein, expressed by HEK293 , with C-6*His labeled tag.

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a B7 family member that maintains T cell and myeloid quiescence and is a promising target for combination cancer immunotherapy. VISTA,a type I transmembrane protein, is primarily expressed in hematopoietic cells. VISTA activity reprograms macrophages towards reduced production of proinflammatory cytokines and increased production of interleukin (IL)-10 and other anti-inflammatory mediators. VISTA not only acts as a ligand expressed on antigenpresenting cells, but also functions as a receptor on T cells. VISTA is an immune checkpoint receptor expressed on tumor-infiltrating T lymphocytes (TILs) and myeloid cells, leading to suppression of T cell activation, proliferation, and cytokine production, thereby promoting immune evasion and survival in a variety of human cancers, such as prostate cancer, non-small cell lung cancer (NSCLC), and colorectal carcinoma. VISTA is overexpressed in tumor tissues and functions as a co-stimulatory molecule^[1][2][3].

Cynomolgus

HEK293

C-6*His

A0A2K5UV12 (F33-A194)

102116468  [NCBI]

Partial

FKVATLYSLYVCPEGQNVTLTCRVFGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSSCVAYPSSSQESENITAA

Approximately 30-50 kDa, based on SDS-PAGE under reducing conditions.

≥ 95%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.